A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
NCT02633657
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
lack of enrollment
Conditions
RLS
Interventions
DRUG:
HORIZANT 300 mg
Sponsor
XenoPort, Inc.